Valuation: Kintor Pharmaceutical Limited

Market Cap 72Cr 11Cr 9.25Cr 8.66Cr 7.93Cr 15Cr 1.02TCr 15Cr 101.39Cr 40Cr 508.34Cr 40Cr 39Cr 1.69TCr P/E 2024
-2.53x
P/E 2025 -3.96x
Enterprise Value 77Cr 11Cr 9.95Cr 9.31Cr 8.52Cr 16Cr 1.09TCr 16Cr 108.97Cr 43Cr 546.35Cr 43Cr 42Cr 1.82TCr EV / Sales 2024
7,57,94,130x
EV / Sales 2025 2,82,45,180x
Free-Float
83.02%
Yield 2024 *
-
Yield 2025 -
1 day-25.22%
1 month-30.17%
3 months-58.24%
6 months-48.13%
Current year-20.37%
1 month 0.17
Extreme 0.172
0.25
Current year 0.17
Extreme 0.172
0.57
1 year 0.17
Extreme 0.172
0.57
3 years 0.08
Extreme 0.0835
0.57
5 years 0.08
Extreme 0.0835
11.8
10 years 0.08
Extreme 0.0835
11.8
Manager TitleAgeSince
Chief Executive Officer 64 24/03/2009
Director of Finance/CFO 49 14/04/2023
Chief Tech/Sci/R&D Officer 49 01/09/2020
Director TitleAgeSince
Director/Board Member 62 12/08/2019
Director/Board Member 61 12/08/2019
Chairman 64 24/03/2009
Change 5-day change 1-year change 3-year change Capi.($)
-25.22%-.--% - - 10Cr
-3.25%+12.81%+52.96%+88.86% 6.49TCr
+0.69%-2.81%+25.84%+68.41% 5.41TCr
-1.07%-1.89%-17.90%-14.36% 2.32TCr
+33.86%+28.54%+18.76%+502.77% 2.15TCr
+1.87%+5.08%+29.88%-7.94% 2.13TCr
-0.79%+0.54%+31.17%-25.84% 1.79TCr
-3.37%+19.44%+211.98%+369.13% 1.7TCr
+3.29%+2.09%+17.32%+586.49% 1.5TCr
-7.94%-5.66%+39.35%+157.52% 1.43TCr
Average -3.47%+3.37%+45.49%+191.67% 2.77TCr
Weighted average by Cap. -1.10%+3.64%+41.95%+147.01%

Financials

2024 2025
Net sales 5 0.74 0.64 0.6 0.55 1.04 70.53 1.05 7.04 2.76 35.29 2.78 2.72 117.5 32.68 4.85 4.2 3.93 3.6 6.78 461 6.9 46 18.04 230.64 18.2 17.8 768.02
Net income -16Cr -2.3Cr -2Cr -1.87Cr -1.71Cr -3.22Cr -219.05Cr -3.28Cr -22Cr -8.57Cr -109.59Cr -8.65Cr -8.46Cr -364.93Cr -20Cr -2.97Cr -2.57Cr -2.41Cr -2.2Cr -4.15Cr -282.26Cr -4.22Cr -28Cr -11Cr -141.22Cr -11Cr -11Cr -470.25Cr
Net Debt -1.57Cr -23.25L -20.14L -18.85L -17.25L -32.52L -22Cr -33.08L -2.21Cr -86.57L -11Cr -87.3L -85.41L -37Cr 5.39Cr 79.88L 69.2L 64.76L 59.27L 1.12Cr 76Cr 1.14Cr 7.58Cr 2.97Cr 38Cr 3Cr 2.93Cr 126.57Cr
Logo Kintor Pharmaceutical Limited
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.
Employees
123
Date Price Change Volume

Annual profits - Rate of surprise